Search

Your search keyword '"Gaujoux-Viala, Cécile"' showing total 285 results
Start Over Author "Gaujoux-Viala, Cécile"
285 results on '"Gaujoux-Viala, Cécile"'

2. 2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis

Author

Fautrel, Bruno, Kedra, Joanna, Rempenault, Claire, Juge, Pierre-Antoine, Drouet, Juliette, Avouac, Jérôme, Baillet, Athan, Brocq, Olivier, Alegria, Guillermo Carvajal, Constantin, Arnaud, Dernis, Emmanuelle, Gaujoux-Viala, Cécile, Goëb, Vincent, Gottenberg, Jacques-Eric, Le Goff, Benoit, Marotte, Hubert, Richez, Christophe, Salmon, Jean-Hugues, Saraux, Alain, Senbel, Eric, Seror, Raphaèle, Tournadre, Anne, Vittecoq, Olivier, Escaffre, Pascale, Vacher, Danielle, Dieudé, Philippe, and Daien, Claire

Published
2024
Full Text
View/download PDF

3. Actualisation 2024 des recommandations de la Société française de rhumatologie pour le diagnostic et la prise en charge des personnes souffrant de polyarthrite rhumatoïde

Author

Fautrel, Bruno, Kedra, Joanna, Rempenault, Claire, Juge, Pierre-Antoine, Drouet, Juliette, Avouac, Jérôme, Baillet, Athan, Brocq, Olivier, Alegria, Guillermo Carvajal, Constantin, Arnaud, Dernis, Emmanuelle, Gaujoux-Viala, Cécile, Goëb, Vincent, Gottenberg, Jacques-Eric, Le Goff, Benoit, Marotte, Hubert, Richez, Christophe, Salmon, Jean-Hugues, Saraux, Alain, Senbel, Eric, Seror, Raphaèle, Tournadre, Anne, Vittecoq, Olivier, Escaffre, Pascale, Vacher, Danielle, Dieudé, Philippe, and Daien, Claire

Published
2024
Full Text
View/download PDF

18. Conventional radiography in juvenile idiopathic arthritis: Joint recommendations from the French societies for rheumatology, radiology and paediatric rheumatology

Author

Marteau, Pauline, Adamsbaum, Catherine, Rossi-Semerano, Linda, De Bandt, Michel, Lemelle, Irène, Deslandre, Chantal, Tran, Tu Anh, Lohse, Anne, Solau-Gervais, Elisabeth, Sordet, Christelle, Pillet, Pascal, Bader-Meunier, Brigitte, Wipff, Julien, Gaujoux-Viala, Cécile, Breton, Sylvain, and Devauchelle-Pensec, Valérie

Published
2018
Full Text
View/download PDF

30. Abatacept therapy and safety management

Author

Pham, Thao, Bachelez, Hervé, Berthelot, Jean-Marie, Blacher, Jacques, Claudepierre, Pascal, Constantin, Arnaud, Fautrel, Bruno, Gaujoux-Viala, Cécile, Goëb, Vincent, Gossec, Laure, Goupille, Philippe, Guillaume-Czitrom, Séverine, Hachulla, Eric, Lequerré, Thierry, Marolleau, Jean-Pierre, Martinez, Valérie, Masson, Charles, Mouthon, Luc, Puéchal, Xavier, Richette, Pascal, Saraux, Alain, Schaeverbeke, Thierry, Soubrier, Martin, Viguier, Manuelle, Vittecoq, Olivier, Wendling, Daniel, Mariette, Xavier, and Sibilia, Jean

Published
2012
Full Text
View/download PDF

35. Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta‐Analysis.

Author

Wetzman, Amélie, Lukas, Cédric, Gaujoux‐Viala, Cécile, Mamtani, Ronac, Barnetche, Thomas, Combe, Bernard, Morel, Jacques, and Szafors, Paulina

Subjects
RHEUMATOID arthritis, DISEASE risk factors, TUMOR necrosis factors, ANTIRHEUMATIC agents, PSORIATIC arthritis
Abstract

Objective: To determine the risk of recurrent or new malignancy with exposure to targeted disease‐modifying antirheumatic drugs (DMARDs) in adults with rheumatoid arthritis (RA), axial spondyloarthritis (SpA), or psoriatic arthritis (PsA) and a history of cancer. Methods: We performed a systematic search of the literature for articles published up to June 2019 that investigated adults with RA, axial SpA, or PsA who had a history of cancer and received biologic or targeted synthetic DMARDs (bDMARDs or tsDMARDs). We compared the risk of relapse or occurrence of new cancer between patients with and without bDMARDs. Rate ratios (RRs) with 95% confidence intervals (95% CIs) were estimated. The heterogeneity of the studies was evaluated by the Cochran Q test and the I2 statistic. Results: We included 24 observational studies of chronic inflammatory arthritis; of those, 12 were included in the meta‐analysis of RA patients receiving bDMARDs. As compared with RA patients with a history of cancer and not receiving bDMARDs, for those receiving any bDMARD, the overall RR for risk of neoplasia was 1.09 (95% CI 0.92–1.32; P = 0.31, I2 = 8%); with tumor necrosis factor inhibitors, it was 1.11 (95% CI 0.85–1.46; P = 0.45, I2 = 48%); and with rituximab, it was 0.79 (95% CI 0.41–1.53; P = 0.49, I2 = 0%). The RR for risk of recurrence for skin cancer was 1.32 (95% CI 1.02–1.72; P = 0.04, I2 = 0%) and for breast neoplasia 1.21 (95% CI 0.84–1.72; P = 0.31, I2 = 0%). Conclusion: Apart from skin cancers including melanoma, the risk of recurrent or new cancer is not increased with the initiation of bDMARDs for RA as compared with no bDMARDs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Comparaison des performances de l’échographie mode B et de l’imagerie par résonance magnétique pour la recherche d’érosions osseuses au cours de la polyarthrite rhumatoïde : analyse systématique de la littérature et méta-analyse

Author

Baillet, Athan, Gaujoux-Viala, Cécile, Mouterde, Gaël, Pham, Thao, Tebib, Jacques, Saraux, Alain, Cantagrel, Alain, Claudepierre, Pascal, Fautrel, Bruno, Maillefert, Jean-Francis, Schaeverbeke, Thierry, Wendling, Daniel, Loët, Xavier Le, and Gaudin, Philippe

Published
2009
Full Text
View/download PDF

42. Patient Global Assessment of Disease Activity and Radiographic Progression in Early Arthritis: Three-Year Results From the ESPOIR Cohort.

Author

Ferreira, Ricardo J. O., Fautrel, Bruno, Saraux, Alain, Gaujoux‐Viala, Cécile, Rat, Anne‐Christine, Guillemin, Francis, da Silva, José A. P., Dougados, Maxime, Gossec, Laure, Gaujoux-Viala, Cécile, and Rat, Anne-Christine

Subjects
DISEASE progression, DISEASE remission, ARTHRITIS diagnosis, TREATMENT of arthritis, ARTHRITIS patients
Abstract

Objective: To determine whether patient global assessment of disease activity (PtGA) over the first year of disease course, as part of a Boolean-based definition of remission and considered individually, had a significant relationship with structural progression over 3 years in patients with early arthritis.Methods: We conducted a prospective, observational study using ESPOIR (Étude et Suivi des Polyarthrites Indifférenciées Récentes) cohort data. Remission states were defined as 1) 4-variable remission, which included a tender joint count in 28 joints, a swollen joint count in 28 joints (SJC28), a C-reactive protein (CRP; mg/dl) level, and PtGA (scored 0-10, all scores of ≤1); 2) PtGA near remission, which included the same parameters as 4-variable remission with only PtGA >1 (of a maximum possible score of 10); 3) 3-variable remission (sum of the proportion of patients in 4-variable remission and the proportion of patients in PtGA near remission); or 4) nonremission. The strictest status satisfied both at 6 and 12 months was considered. Radiographic progression was determined as a change of ≥5 points in the total Sharp/van der Heijde score (ΔSHS) from baseline to 3 years. The predictive capacities for radiographic damage of different remission definitions were assessed by odds ratio (OR). The association between each individual component of remission with ΔSHS was tested through multivariate linear regression analyses.Results: Among 520 patients, 7% achieved 4-variable remission and 12% achieved PtGA near remission. Radiographic progression was observed in 29% of patients who achieved 4-variable remission (OR versus nonremission; OR 0.32 [95% confidence interval (95% CI) 0.15, 0.68]) and in 45% of patients with PtGA near remission (OR 0.65 [95% CI 0.38, 1.11]); the comparison was not statistically different (OR 0.49 [95% CI 0.20, 1.18]). In 3-variable remission, radiographic progression was observed in 39%. Of the individual components, only the SJC28 and CRP level were associated with radiographic progression.Conclusion: All definitions of remission led to low structural degradation in early arthritis, and 4-variable remission led to less radiographic progression than PtGA near remission, but without a statistically significant difference. Both 4-variable remission and 3-variable remission appear to be useful targets when aiming for structural nonprogression. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

45. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Author

Smolen, Josef S, Landewé, Robert, Breedveld, Ferdinand C, Buch, Maya, Burmester, Gerd, Dougados, Maxime, Emery, Paul, Gaujoux-Viala, Cécile, Gossec, Laure, Nam, Jackie, Ramiro, Sofia, Winthrop, Kevin, de Wit, Maarten, Aletaha, Daniel, Betteridge, Neil, Bijlsma, Johannes W J, Boers, Maarten, Buttgereit, Frank, Combe, Bernard, Cutolo, Maurizio, Damjanov, Nemanja, Hazes, Johanna M W, Kouloumas, Marios, Kvien, Tore K, Mariette, Xavier, Pavelka, Karel, van Riel, Piet L C M, Rubbert-Roth, Andrea, Scholte-Voshaar, Marieke, Scott, David L, Sokka-Isler, Tuulikki, Wong, John B, and van der Heijde, Désirée

Published
2014
Full Text
View/download PDF

47. Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index

Author

Bykerk, Vivian P., primary, Blauvelt, Andrew, additional, Curtis, Jeffrey R., additional, Gaujoux‐Viala, Cécile, additional, Kvien, Tore K., additional, Winthrop, Kevin, additional, Tilt, Nicola, additional, Popova, Christina, additional, Mariette, Xavier, additional, and Haraoui, Boulos, additional

Published
2021
Full Text
View/download PDF

49. Patient global assessment and radiographic progression in early arthritis: 3‐year results from the ESPOIR cohort

Author

Ferreira, Ricardo J.O., Fautrel, Bruno, Saraux, Alain, Gaujoux‐Viala, Cécile, Rat, Anne‐Christine, Guillemin, Francis, Da Silva, José A.P., Dougados, Maxime, Gossec, Laure, Health Sciences Research Unit: Nursing [Coimbra, Portugal] (UICiSA:E), Escola Superior de Enfermagem de Coimbra [Coimbra, Portugal], Department of Rheumatology (COIMBRA - Rhumato), Universidade de Coimbra [Coimbra], Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CRI-IMIDIATE Clinical Research Network, CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Service de Rhumatologie [CHRU Nîmes], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service de Rhumatologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Centre d'investigation clinique - Epidémiologie clinique [Nancy] (CIC-EC), Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Faculty of Medicine, University of Coimbra, 3000, Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Equipe 2 : ECSTRA - Epidémiologie Clinique, STatistique, pour la Recherche en Santé (CRESS - U1153), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), and Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)

Subjects
Quality of life, Predictive Value of Tests, Remission, Patient-reported Outcomes, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Rheumatoid arthritis, Structural damage, Patient global assessment
Abstract

International audience; Objectives: To determine if patient global assessment (PGA), as part of Boolean-based definition of remission and individually considered, over the first year of disease course had a significant relationship with structural progression over 3 years in patients with early arthritis (EA).Methods: Prospective, observational study using ESPOIR cohort data. Remission states were defined as (a) 4v-remission: tender (TJC28), swollen 28-joint counts (SJC28), C-Reactive protein (mg/dL), and PGA (0-10) all ≤1; (b) PGA-near-remission: same parameters with only PGA>1/10; (c) 3v-remission (sum of previous groups) or (d) non-remission. The strictest status satisfied both at 6- and 12-months was considered. Radiographic progression was determined as a change in total Sharp-van der Heijde score from baseline to 3 years (ΔSHS) ≥5 points. The predictive capacities for radiographic damage of different remission definitions were assessed by Odds Ratio (OR). The association between each individual component of remission with ΔSHS was tested through multivariate linear regression analyses.Results: Among 520 patients, 7% achieved 4v-remission and 12% PGA-near-remission. Radiographic progression was observed in 29% of patients in 4v-remission (OR versus non-remission, OR=0.32 [95%CI:0.15-0.68]) and in 45% of patients in PGA-near-remission (OR=0.65 [0.38-1.11]); the comparison was not statistically different (OR=0.49 [0.20-1.18]). In 3v-remission it was observed in 39%. Of the individual components, only SJC28 and CRP were associated with radiographic progression.Conclusion: All definitions of remission led to low structural degradation in EA: 4v-remission led to less progression than PGA-near-remission but without a statistically significant difference. Both 4v-remission and 3v-remission appear useful targets when aiming at structural non-progression.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results